ATE364618T1 - Antikörper gegen das muc18-antigen - Google Patents
Antikörper gegen das muc18-antigenInfo
- Publication number
- ATE364618T1 ATE364618T1 AT02797516T AT02797516T ATE364618T1 AT E364618 T1 ATE364618 T1 AT E364618T1 AT 02797516 T AT02797516 T AT 02797516T AT 02797516 T AT02797516 T AT 02797516T AT E364618 T1 ATE364618 T1 AT E364618T1
- Authority
- AT
- Austria
- Prior art keywords
- antibodies
- muc18
- muc18 antigen
- antigen
- melanomas
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34629901P | 2001-12-28 | 2001-12-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE364618T1 true ATE364618T1 (de) | 2007-07-15 |
Family
ID=23358784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02797516T ATE364618T1 (de) | 2001-12-28 | 2002-12-26 | Antikörper gegen das muc18-antigen |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6924360B2 (de) |
| EP (1) | EP1470146B8 (de) |
| JP (1) | JP2005514425A (de) |
| AT (1) | ATE364618T1 (de) |
| AU (1) | AU2002361886A1 (de) |
| CA (1) | CA2471849A1 (de) |
| DE (1) | DE60220719T2 (de) |
| ES (1) | ES2289174T3 (de) |
| WO (1) | WO2003057838A2 (de) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030068319A1 (en) * | 2001-03-23 | 2003-04-10 | Menashe Bar-Eli | Methods for inhibition of angiogenesis, tumor growth and metastasis by fully human anti-IL8 and anti-MUC18 in diverse types of tumors |
| US7521053B2 (en) * | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| US7658924B2 (en) * | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| PL229487B1 (pl) * | 2002-11-12 | 2018-07-31 | Brigham & Womens Hospital Inc | Kompozycja zawierająca polimer β-1,6-glukozaminy, kompozycja zawierająca przeciwciało, kompozycja farmaceutyczna, sposób wytwarzania wyodrębnionego polisacharydu, sposób identyfikacji obecności deacetylowanej poli-N-acetyloglukozaminy (dPNAG) i/ lub poli-N-acetyloglukozaminy (PNAG), wyodrębniony polisacharyd do zastosowania w leczeniu lub profilaktyce zakażenia, wyodrębniony polisacharyd do zastosowania do wytwarzania przeciwciał, w tym przeciwciał monoklonalnych, wyodrębniony polisacharyd do zastosowania w identyfikacji przeciwciała monoklonalnego |
| ES2415358T3 (es) * | 2004-04-21 | 2013-07-25 | The Brigham And Women's Hospital, Inc. | Péptidos de fijación a la poli-N-acetil glucosamina (PNAG/DPNAG) y procedimientos para el uso de los mismos |
| EP1976878A4 (de) * | 2006-01-30 | 2010-06-02 | Fred Hutchinson Cancer Res Fou | Folge aus der variablen stro-1-antikörperregion |
| JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
| CN102159540B (zh) | 2008-07-21 | 2015-08-12 | 布赖汉姆妇女医院 | 与合成的β-1,6葡糖胺寡糖相关的方法和组合物 |
| WO2010045469A2 (en) | 2008-10-15 | 2010-04-22 | The Board Of Regents Of The University Of Texas System | Muc18 targeting peptides |
| SG10201407757XA (en) * | 2009-10-23 | 2015-01-29 | Millennium Pharm Inc | Anti-gcc antibody molecules and related compositions and methods |
| AU2013251312B2 (en) | 2012-04-27 | 2018-03-22 | Takeda Pharmaceutical Company Limited | Anti-GCC antibody molecules and use of same to test for susceptibility to GCC-targeted therapy |
| TWI595007B (zh) | 2012-09-10 | 2017-08-11 | Neotope Biosciences Ltd | 抗ｍｃａｍ抗體及相關使用方法 |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| WO2014089152A1 (en) * | 2012-12-04 | 2014-06-12 | University Of Maryland, Baltimore | Hiv-1 env-binding antibodies, fusion proteins, and methods of use |
| US9708375B2 (en) | 2013-03-15 | 2017-07-18 | Amgen Inc. | Inhibitory polypeptides specific to WNT inhibitors |
| EP3041863A4 (de) | 2013-09-05 | 2017-08-16 | Amgen Inc. | Fc-haltige moleküle mit vorhersagbaren, konsistenten und reproduzierbaren glycoformprofilen |
| ES2686692T3 (es) | 2013-09-24 | 2018-10-19 | Oncoinvent As | Anticuerpo monoclonal anti CD146 |
| PT3116911T (pt) | 2014-03-12 | 2019-09-04 | Prothena Biosciences Ltd | Anticorpos anti-mcam e métodos de utilização associados |
| JP2017514458A (ja) | 2014-03-12 | 2017-06-08 | プロセナ バイオサイエンシーズ リミテッド | Ｌｇ４−５に対して特異的な抗−ラミニン４抗体 |
| TW201623331A (zh) | 2014-03-12 | 2016-07-01 | 普羅帝納生物科學公司 | 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法 |
| KR20160131082A (ko) | 2014-03-12 | 2016-11-15 | 프로테나 바이오사이언시즈 리미티드 | Lg1-3에 특이적인 항-라미닌4 항체 |
| US10156562B2 (en) | 2014-05-16 | 2018-12-18 | Amgen Inc. | Assay for detecting Th1 and Th2 cell populations |
| TWI718121B (zh) | 2015-01-28 | 2021-02-11 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
| TWI769570B (zh) | 2015-01-28 | 2022-07-01 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
| TWI786505B (zh) | 2015-01-28 | 2022-12-11 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
| WO2017046774A2 (en) | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
| EP3350226A2 (de) | 2015-09-16 | 2018-07-25 | Prothena Biosciences Limited | Verwendung von anti-mcam-antikörpern zur behandlung oder prophylaxe von riesenzellarteriitis, polymyalgia rheumatica oder takayasu-arteriitis |
| WO2017149513A1 (en) | 2016-03-03 | 2017-09-08 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
| WO2017153953A1 (en) | 2016-03-09 | 2017-09-14 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases |
| WO2017153955A1 (en) | 2016-03-09 | 2017-09-14 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases |
| MY198194A (en) | 2016-05-02 | 2023-08-09 | Prothena Biosciences Ltd | Antibodies Recognizing Tau |
| MX2018013386A (es) | 2016-05-02 | 2019-02-28 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau. |
| WO2017208210A1 (en) | 2016-06-03 | 2017-12-07 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
| WO2018007924A2 (en) | 2016-07-02 | 2018-01-11 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| WO2018007922A2 (en) | 2016-07-02 | 2018-01-11 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| JP7016470B2 (ja) | 2016-07-02 | 2022-02-07 | プロセナ バイオサイエンシーズ リミテッド | 抗トランスサイレチン抗体 |
| CA3056011A1 (en) | 2017-03-14 | 2018-09-20 | Amgen Inc. | Control of total afucosylated glycoforms of antibodies produced in cell culture |
| KR102784294B1 (ko) | 2017-05-02 | 2025-03-19 | 프로테나 바이오사이언시즈 리미티드 | 타우 인식 항체 |
| WO2018220467A1 (en) | 2017-05-30 | 2018-12-06 | Foroogh Nejatollahi | Anti-muc18 human immunotoxin and applications thereof |
| AU2018345807B2 (en) | 2017-10-06 | 2025-02-06 | Novo Nordisk A/S | Methods of detecting transthyretin |
| US12325737B2 (en) | 2018-03-26 | 2025-06-10 | Amgen Inc. | Total afucosylated glycoforms of antibodies produced in cell culture |
| CU24781B1 (es) | 2018-11-08 | 2026-02-09 | Prothena Biosciences Ltd | Anticuerpos humanizados que reconocen tau |
| WO2020132190A1 (en) | 2018-12-21 | 2020-06-25 | Multitude Inc. | Antibodies specific to muc18 |
| JP7578289B2 (ja) * | 2018-12-21 | 2024-11-06 | マルチチュード インコーポレーテッド | Ｍｕｃ１８に特異的な抗体 |
| US12397014B2 (en) | 2019-02-05 | 2025-08-26 | The Brigham And Women's Hospital, Inc. | Polysaccharide compositions for use in treating filariasis |
| JP7630834B2 (ja) | 2019-03-03 | 2025-02-18 | プロセナ バイオサイエンシーズ リミテッド | タウ認識抗体 |
| BR112022005583A2 (pt) | 2019-09-26 | 2022-09-20 | Amgen Inc | Métodos para a produção de composições de anticorpos |
| US20230273126A1 (en) | 2020-06-04 | 2023-08-31 | Amgen Inc. | Assessment of cleaning procedures of a biotherapeutic manufacturing process |
| BR112022026508A2 (pt) | 2020-06-24 | 2023-03-07 | Prothena Biosciences Ltd | Anticorpos que reconhecem sortilina |
| KR20230087539A (ko) | 2020-10-15 | 2023-06-16 | 암젠 인크 | 항체 생산 방법에서의 상대적인 비결합 글리칸 |
| EP4352094A1 (de) | 2021-06-07 | 2024-04-17 | Amgen Inc. | Verwendung von fucosidase zur steuerung des afucosylierungsniveaus glykosylierter proteine |
| US20250076309A1 (en) | 2021-10-05 | 2025-03-06 | Amgen Inc. | Fc-gamma receptor ii binding and glycan content |
| EP4463135A2 (de) | 2022-01-10 | 2024-11-20 | Sana Biotechnology, Inc. | Verfahren zur ex-vivo-dosierung und -verabreichung von lipidpartikeln oder viralen vektoren sowie entsprechende systeme und verwendungen |
| WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2024081820A1 (en) | 2022-10-13 | 2024-04-18 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
| WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
| AU2024256160A1 (en) | 2023-04-20 | 2025-10-02 | Amgen Inc. | Methods of determining relative unpaired glycan content |
| EP4716750A1 (de) | 2023-05-23 | 2026-04-01 | Sana Biotechnology, Inc. | Tandem-fusogene und verwandte lipidpartikel |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| CN117069848B (zh) * | 2023-08-02 | 2025-02-28 | 武汉爱博泰克生物科技有限公司 | 抗人cd146兔单克隆抗体及其应用 |
| WO2025038600A1 (en) | 2023-08-14 | 2025-02-20 | Amgen Inc. | Methods for reducing yellow color |
| WO2025059486A1 (en) | 2023-09-15 | 2025-03-20 | Prothena Biosciences Limited | Anti-tdp-43 antibodies and uses thereof |
| TW202530246A (zh) | 2023-09-15 | 2025-08-01 | 愛爾蘭商歐賽爾普羅希那有限公司 | 細胞穿透劑及其用途 |
| AR133834A1 (es) | 2023-09-15 | 2025-11-05 | Prothena Biosciences Ltd | Agentes de penetración célular y sus usos |
| AU2024341632A1 (en) | 2023-09-15 | 2026-04-23 | Prothena Biosciences Limited | Compositions and methods of reducing immunogenicity and improving stability of antibodies |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025101820A1 (en) | 2023-11-08 | 2025-05-15 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
| WO2025184529A1 (en) | 2024-03-01 | 2025-09-04 | Sana Biotechnology, Inc. | Viral particles with fusogen display and related compositions and methods |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
| DK0486622T3 (da) | 1989-08-09 | 1999-07-19 | Rhomed Inc | Direkte radiomærkning af antistoffer og andre proteiner med technetium eller rhenium |
| US5697901A (en) | 1989-12-14 | 1997-12-16 | Elof Eriksson | Gene delivery by microneedle injection |
| US6833268B1 (en) * | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
| US20030068319A1 (en) | 2001-03-23 | 2003-04-10 | Menashe Bar-Eli | Methods for inhibition of angiogenesis, tumor growth and metastasis by fully human anti-IL8 and anti-MUC18 in diverse types of tumors |
| DE60226499D1 (de) | 2001-12-28 | 2008-06-19 | Amgen Fremont Inc | Verwendung von antikörpern gegen das muc18-antigen |
-
2002
- 2002-12-26 EP EP02797516A patent/EP1470146B8/de not_active Expired - Lifetime
- 2002-12-26 WO PCT/US2002/041581 patent/WO2003057838A2/en not_active Ceased
- 2002-12-26 AU AU2002361886A patent/AU2002361886A1/en not_active Abandoned
- 2002-12-26 US US10/330,613 patent/US6924360B2/en not_active Expired - Fee Related
- 2002-12-26 JP JP2003558140A patent/JP2005514425A/ja active Pending
- 2002-12-26 AT AT02797516T patent/ATE364618T1/de not_active IP Right Cessation
- 2002-12-26 DE DE60220719T patent/DE60220719T2/de not_active Expired - Fee Related
- 2002-12-26 ES ES02797516T patent/ES2289174T3/es not_active Expired - Lifetime
- 2002-12-26 CA CA002471849A patent/CA2471849A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002361886A1 (en) | 2003-07-24 |
| US6924360B2 (en) | 2005-08-02 |
| DE60220719T2 (de) | 2008-03-06 |
| JP2005514425A (ja) | 2005-05-19 |
| US20030147809A1 (en) | 2003-08-07 |
| DE60220719D1 (de) | 2007-07-26 |
| EP1470146A2 (de) | 2004-10-27 |
| CA2471849A1 (en) | 2003-07-17 |
| EP1470146A4 (de) | 2005-07-13 |
| EP1470146B1 (de) | 2007-06-13 |
| ES2289174T3 (es) | 2008-02-01 |
| EP1470146B8 (de) | 2007-09-12 |
| WO2003057838A2 (en) | 2003-07-17 |
| WO2003057838A3 (en) | 2004-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE364618T1 (de) | Antikörper gegen das muc18-antigen | |
| ATE394121T1 (de) | Verwendung von antikörpern gegen das muc18- antigen | |
| WO2003057837A8 (en) | Methods for using anti-muc18 antibodies | |
| MX338122B (es) | Epitopes terapeuticos y usos de los mismos. | |
| EP1238985A4 (de) | Menschlicher antikörper gegen gangliosid gd3 für die transplantationskomplementarität bestimmente regionund derivate des antikörpers gegen das gangliosid gd3 | |
| IN2012DN00313A (de) | ||
| TW200505942A (en) | Antibody molecules having specificity for human IL-1β | |
| TNSN05300A1 (en) | Treatment with anti-vegf antibodies | |
| TR200102733T2 (tr) | IL-18 kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri | |
| BRPI0411784A (pt) | anticorpos contra interleucina -22 e usos para os mesmos | |
| TR200103233T2 (tr) | Antikolinerjik etkili bileşik ve ß-mimetikler bazında yeni ilaç bileşimleri. | |
| BG101024A (bg) | Моноклонално антитяло срещу сd44v6 | |
| MXPA02011656A (es) | Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos. | |
| TR200102021T2 (tr) | TWEAK ve TWEAK reseptörü antagonistleri ve bunların imünolojik bozuklukların iyileştirilmesi için kullanımları | |
| EA200401341A1 (ru) | Применение остеопротегерина для лечения и/или профилактики фиброзного заболевания | |
| CY1111946T1 (el) | To (1s, 5s) -3-(5,6-διχλωρο-3-πυριδινυλο)-3, 6-διαζαδικυ-κλο[3.2.0]επτανιο ειναι ενας αποτελεσματiκος αναλγητικος παραγοντας | |
| ATE407147T1 (de) | Fab-fragmente humaner monoklonaler antikörper mit neutralisierender aktivität gegen das hcv e2 glycoprotein | |
| EP2434022A3 (de) | Verwendung von A33-Antigenen und JAM-IT | |
| EP2347767A3 (de) | Auf dem Targeting früher Aktivierungsmoleküle basierende Immunregulierung | |
| DE602004019541D1 (de) | Cycloalkyläbü kondensierte indole | |
| ATE538376T1 (de) | Herstellung polyklonaler, monospezifischer antikörper gegen die upar-varianten del4, del5 und del4+5 sowie deren verwendung für diagnostische und therapeutische zwecke | |
| AU2003225900A1 (en) | Antibody disulfide isomers, use thereof, and methods of analyzing same | |
| EA200600314A1 (ru) | Использование растворимого cd164 при воспалительных и/или аутоимунных нарушениях | |
| WO2006113723A3 (en) | Compositions and methods for diagnosing, predicting therapeutic response of, and monitoring autoimmune disease | |
| DE60021409D1 (de) | Neurokinin b vorläufer aus menschlicher plazenta |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |